Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You Why Wall Street Gave Up on Pfizer—and Why That May Be a MistakeAuthor: Jeffrey Neal Johnson. Originally Published: 12/31/2025. 
Summary - Pfizer trades at a historic discount compared to its peers while paying a dividend yield that significantly outperforms the broader market average.
- Strategic acquisitions have established a robust pipeline of next-generation cancer treatments, which are driving growth.
- Management has aggressively re-entered the weight-loss market with new assets, including one that offers a convenient monthly dosing schedule for patients.
The market in 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were largely ignored. Nowhere is that more evident than with Pfizer Inc. (NYSE: PFE). Trading near multi-year lows around $25, the company finishes the year as one of the most unloved assets in the S&P 500. Pessimism seemed justified: Pfizer spent the past two years battling a perfect storm. Revenue from COVID-19 products vanished faster than anticipated, high-profile pipeline candidates failed in clinical trials, and activist investors launched a public campaign against management. While headlines focus on Tesla's car sales, tech analyst Jeff Brown says the real story is Tesla's role in a $25 trillion AI revolution — one that Nvidia's CEO himself has called a "multi-trillion-dollar future industry" — and he's uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough. Click here now to see the full report Yet investing often requires venturing where others refuse to go. With activist Starboard Value exiting in November and management resetting financial guidance to more realistic levels, much of the bad news is already out. The negative surprises appear priced in, and Pfizer's stock price has likely found a floor. As we enter 2026, Pfizer presents a rare setup: a blue-chip company trading at a deeply discounted valuation, offering a solid dividend yield while it quietly rebuilds its growth prospects. The Mathematical Case: Why the Price Is Wrong For value investors, the argument for Pfizer is straightforward. The market is pricing the company as if its earnings will permanently shrink, creating a wide gap between the share price and the firm's actual cash generation. A Historic Valuation Gap Pfizer currently trades at a forward price-to-earnings ratio (P/E) of roughly 8.6x. By contrast, the average company in the pharmaceutical sector trades at 15x–20x earnings, and high-growth peers like Eli Lilly (NYSE: LLY) command significantly higher multiples. A P/E near 8.6x implies the market expects virtually no growth. That sets a very low bar: Pfizer does not need a miracle to see the stock rise; it simply needs to show stability and modest improvement. Any positive earnings surprise could trigger multiple expansion, lifting the stock toward industry norms. The Dividend Shield While investors wait for repricing, they are handsomely compensated to hold the shares. - Annual payout: $1.72 per share.
- Current yield: Approximately 6.9%.
That yield is roughly four times the S&P 500 average and acts as a margin of safety. Even if the stock price remains flat through 2026, a near-7% dividend yield provides a solid baseline return that beats most savings accounts and government bonds. Management is supporting the dividend with a $4 billion cost-saving initiative. By cutting administrative bloat and optimizing manufacturing, the company is preserving the cash flow needed to keep those quarterly payouts intact. The New Foundation: Oncology Takes the Lead The most common criticism of Pfizer is that it has a growth gap left by the decline of its COVID business. To fill that hole, the company has pivoted aggressively toward oncology. Guided-missile technology The crown jewel of Pfizer's 2023 Seagen acquisition is leadership in Antibody-Drug Conjugates (ADCs). Where traditional chemotherapy can damage healthy tissue along with tumors, ADCs act more like guided missiles — identifying specific cancer cells and delivering a toxic payload directly. This technology is already producing results. The Seagen portfolio contributed approximately $3.4 billion in revenue in 2024, driven in part by strong sales of Padcev for bladder cancer. Navigating the bumps The path has not been perfectly smooth. In December 2025, the company reported a safety signal involving Hympavzi in a trial extension; the news caused a temporary stock reaction but did not derail the broader thesis. Pfizer's oncology pipeline remains deep — more than 60 programs are in development — and the company has continued to reinforce the pipeline through deals, including licensing a promising bispecific antibody from 3SBio. Catching Up: The Strategy for Weight Loss Early in 2025, Wall Street largely wrote Pfizer off in the weight-loss drug race after its internal pill, danuglipron, failed to advance. But Pfizer didn't walk away from the trend. In late 2025 it re-entered the market via two strategic transactions. The injectable strategy (Metsera) In November, Pfizer acquired Metsera for about $7 billion, gaining MET-097i — a next-generation injectable candidate. Unlike current market leaders that require weekly injections, MET-097i has the potential for monthly dosing, which could be a major convenience advantage. The oral strategy (YaoPharma) Pfizer also licensed a small-molecule GLP-1 candidate from YaoPharma to pursue an oral alternative for patients who prefer pills over injections. Why this matters At present, the market attributes virtually no value to Pfizer's obesity pipeline. That creates an embedded option for investors: with expectations already at rock bottom, any clinical progress for Metsera's or YaoPharma's assets would be pure upside. Pfizer doesn't need to be first; it only needs to capture a slice of what could become a roughly $100 billion market. The Risk/Reward Equation: 2026 Belongs to Value Pfizer enters 2026 as a company in transition but with a fortified balance sheet. Management has set a conservative revenue floor of about $61 billion for 2026, a realistic target that removes some of the uncertainty that plagued the stock the last two years. For investors, the equation is simple. At roughly $25 per share, downside risk is cushioned by a healthy dividend and historically low valuation. Upside is meaningful: continued oncology growth or positive results from the weight-loss programs could prompt a sharp repricing. Unloved stocks in one year often become standout performers the next. With activist pressure easing and the balance sheet stabilized, Pfizer has shifted from a falling knife to a potential foundational holding for value-minded portfolios. For Pfizer, 2026 may finally be the year the sleeping giant wakes up.
| 
